×

Nasal administration

  • US 9,649,456 B2
  • Filed: 04/07/2008
  • Issued: 05/16/2017
  • Est. Priority Date: 04/05/2007
  • Status: Active Grant
First Claim
Patent Images

1. A method of treating migraine in a human subject by delivering a powdered substance comprising sumatriptan to the posterior region of a nasal cavity of the human subject, the method comprising:

  • inserting a nosepiece into the nasal cavity of the human subject;

    inserting a mouthpiece into the mouth of the human subject;

    the subject exhaling through the mouthpiece to cause closure of the oropharyngeal velum of the subject, wherein the mouthpiece is fluidly connected to the nosepiece, whereby exhaled air from an exhalation breath is delivered through the nosepiece; and

    delivering the powdered substance through the nosepiece to the posterior region of the nasal cavity of the subject via a bi-directional flow through the nasal cavity, wherein the powdered substance is delivered from a container chamber which houses a container which contains the powdered substance, and the container chamber includes an inlet which is fluidly connected to the mouthpiece and an outlet which is fluidly connected to the nosepiece, whereby exhaled air from the exhalation breath acts to entrain the powdered substance and deliver the powdered substance through the nosepiece;

    wherein the powdered substance consists essentially of sumatriptan succinate without introduced excipients or adjuvants and;

    wherein the powdered substance has an untapped bulk density of between about 0.3 g/ml and about 0.5 g/ml;

    wherein the powdered substance comprises a particle size distribution of 10% less than about 20 μ

    m, 50% less than about 50 μ

    m, and 90% less than about 150 μ

    m.

View all claims
  • 6 Assignments
Timeline View
Assignment View
    ×
    ×